## <u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

Mai H. Nguyen

Serial No.:

09/901,339

Filed:

July 9, 2001

Docket:

30448.73USU1

Title:

METHODS FOR DIAGNOSING BREAST CANCER USING NIPPLE FLUID

ARCEIVE 18 2002

**CERTIFICATE UNDER 37 CFR 1.8** 

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on December 18, 2001.

Name: Richelle A

RECEIVED

JAN 0 8 2002 TC 1700

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- Information Disclosure Statement (37 C.F.R. §1.97 (d))
- Form 1449 (Information Disclosure Statement) (2 sheets)
- Exhibits 1 20
- Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

35 No. Arroyo Parkway, Suite 60 Pasadena, California 91103 (626)395-7801

Name: SaraLynn Mandel

Reg. No.: 31,853 Initials: SLM

Customer No. 26,941

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mai H. Nguyen

Examiner:

Not Yet Known

Serial No.:

09/901,339

**Group Art Unit:** 

1743

Filed:

July 9, 2001

Docket No.:

30448.73USU1

Title:

METHODS FOR DIAGNOSING BREAST CANCER USING NIPPLE

**FLUID** 

**CERTIFICATE UNDER 37 CFR 1.8:** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on December 18, 2001.

By: Richelle Ann Domingo

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

TG 1700

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- U.S. Patent No. 5,187,062, 16 February 1993, Sato et al. (Exhibit 1)
- Cheales-Siebenaler, Noreen J., "Induced Lactation in an Adoptive Mother," Journal of Human Lactation, March 1999, 15(1):41-3. (Exhibit 2)
- Foretova, Lenka et al., "Carcinoembryonic Antigen in Breast Nipple Aspirate Fluid," Cancer Epidemiology, Biomarkers and Prevention, March 1998, 7:195-8. (Exhibit 3)
- Fujimoto, Kiyohide et al., "Increased Serum Levels of Basic Fibroblast Growth Factor in Biochemical and Biophysical Research with Renal Cell Carcinoma," Communications, October 15, 1991, 180(1):386-92. (Exhibit 4)

- Gail, Mitchell H. et al., "Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually," *Journal of the National Cancer Institute*, <u>December 20, 1989</u>, 81(24):1879-86. (Exhibit 5)
- Gann, Peter et al., "Mitogenic Growth Factors in Breast Fluid Obtained from Healthy
  Women: Evaluation of Biological and Extraneous Sources of Variability," Cancer
  Epidemiology, Biomarkers and Prevention, June 1997, 6(6):421-8. (Exhibit 6)
- Li, Vincent W. et al., "Microvessel Count and Cerebrospinal Fluid Basic Fibroblast Growth Factor In Children With Brain Tumours," *Lancet*, <u>July 9, 1994</u>, 344:82-6. (Exhibit 7)
- Lin, Richard Y. et al., "Diagnostic and Prognostic Role of Basic Fibroblast Growth Factor in Wilms' Tumor Patients," *Clinical Cancer Research*, March 1995, 1:327-31. (Exhibit 8)
- Nguyen, Mai, "Angiogenic Factors as Tumor Markers," Investigational New Drugs, 1997,
   15:29-37. (Exhibit 9)
- Nguyen, Mai et al., "Elevated Levels of an Angiogenic Peptide, Basic Fibroblast Growth
  Factor, in the Urine of Patients with a Wide Sprectrum of Cancers," *Journal of National*Cancer Institute, March 2, 1994, 86(5):356-61. (Exhibit 10)
- O'Brien, T.S. et al., "Urinary Basic Fibroblast Growth Factor in Patients with Bladder Cancer and Benign Prostatic Hypertrophy," *British Journal of Urology*, 1995, 76:311-4. (Exhibit 11)
- Petrakis, Nicholas L., "Nipple Aspirate Fluid in Epidemiologic Studies of Breast Disease,"
   Epidemiologic Reviews, 1993, 15(1):188-95. (Exhibit 12)

- Rose, David P., "Hormones and Growth Factors in Nipple Aspirates from Normal Women and Benign Breast Disease Patients," Cancer Detection and Prevention, 1992, 16(1):43-51.
   (Exhibit 13)
- Sauter, Edward R. et al., "Prostate-Specific Antigen Levels in Nipple Aspirate Fluid Correlate with Breast Cancer Risk," Cancer Epidemiology, Biomarkers and Prevention, December 1996, 5:967-70. (Exhibit 14)
- Sluitz, G. et al., "Serum Evaluation of Basic Fibroblast Growth Factor in Cervical Cancer Patients," *Cancer Letters*, 1995, 94(2):227-31. (Exhibit 15)
- Takei, Yoshifumi et al., "Serum Concentrations of Basic Fibroblast Growth Factor in Breast Cancer," *Clinical Chemistry*, 1994, 40(10):1980-1. (Exhibit 16)
- Watanabe, H. et al., (Abstract) "Basic Fibroblast Growth Factor in Human Serum A
  Prognostic Test for Breast Cancer," Molecular Biology of the Cell (formerly Cell Regulation)
  Abstracts, September 1992, 3:234a. (Exhibit 17)
- Watanabe, Hiroyuki et al., "A Sensitive Enzyme Immunoassay for Human Basic Fibroblast Growth Factor," Biochemical and Biophysical Research Communications, February 28, 1991, 175(1):229-35. (Exhibit 18)
- Wrensch, Margaret et al., "Breast Cancer Risk Associated with Abnormal Cytology in Nipple
  Aspirates of Breast Fluid and Prior History of Breast Biopsy," American Journal of
  Epidemiology, April 15, 1993, 137(8):829-33. (Exhibit 19)

Mai H. Nguyen

Serial No. 09/901,339

Filed: July 9, 2001

Page 4

Wrensch, Margaret R. et al., "Factors Associated with Obtaining Nipple Aspirate Fluid:

Analysis of 1428 Women and Literative Review," Breast Cancer Research and Treatment,

1990, 15:39-51. (Exhibit 20)

This statement should be considered because it is submitted before the mailing date of the first

Office Action on the merits. In accordance with 37 C.F.R. §1.98(a)(2), copies of each document

or other information listed on the enclosed Form 1449 are provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102

and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish

that the reference(s) are not "prior art." Moreover, Applicants do not represent that the

references have been thoroughly reviewed or that any relevance of any portion of a reference is

intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of

M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

as being considered and initialed by the Examiner, to the undersigned with the next official

communication.

4

Mai H. Nguyen Serial No. 09/901,339 Filed: July 9, 2001 Page 5

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

SaraLynn Mandel

Registration No. 31,853

Sarah B. Adriano

Registration No. 34,470

Attorney for Applicants

Mandel & Adriano

35 No. Arroyo Parkway, Suite 60

Pasadena, California 91103

(626)395-7801

Customer No. 26,941

Application Number CHCENTER 2002 FORM 1449\* Docket Number 30448.73USU1 INFORMATION DISCLOSURE STATEMENT Applicant IN AN APPLICATION Mai H. Nguyen Filing Date (Use several sheets if necessary) July 9, 2001 1743 **U.S. PATENT DOCUMENTS EXAMINER** DOCUMENT NO. DATE NAME CLASS SUBCLASS INITIAL 5,187,062 February 16, 1993 Sato et al. (Exhibit 1) FOREIGN PATENT DOCUMENTS DOCUMENT NO. DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Cheales-Siebenaler, Noreen J., "Induced Lactation in an Adoptive Mother," Journal of Human Lactation, March 1999, 15(1):41-3. (Exhibit 2) Foretova, Lenka et al., "Carcinoembryonic Antigen in Breast Nipple Aspirate Fluid," Cancer Epidemiology, Biomarkers and Prevention, March 1998, 7:195-8. (Exhibit 3) Fujimoto, Kiyohide et al., "Increased Serum Levels of Basic Fibroblast Growth Factor in Patients with Renal Cell Carcinoma," Biochemical and Biophysical Research Communications, October 15, 1991, 180(1):386-92. (Exhibit 4) Gail, Mitchell H. et al., "Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually," Journal of the National Cancer Institute, December 20, 1989, 81(24):1879-86. (Exhibit 5) Gann, Peter et al., "Mitogenic Growth Factors in Breast Fluid Obtained from Healthy Women: Evaluation of Biological and Extraneous Sources of Variability," Cancer Epidemiology, Biomarkers and Prevention, June 1997, 6(6):421-8. (Exhibit 6) Li, Vincent W. et al., "Microvessel Count and Cerebrospinal Fluid Basic Fibroblast Growth Factor In Children With Brain Tumours," Lancet, July 9, 1994, 344:82-6. (Exhibit 7) Lin, Richard Y. et al., "Diagnostic and Prognostic Role of Basic Fibroblast Growth Factor in Wilms' Tumor Patients," Clinical Cancer Research, March 1995, 1:327-31. (Exhibit 8) Nguyen, Mai, "Angiogenic Factors as Tumor Markers," Investigational New Drugs, 1997, 15:29-37. (Exhibit 9) Nguyen, Mai et al., "Elevated Levels of an Angiogenic Peptide, Basic Fibroblast Growth Factor, in the Urine of Patients with a Wide Sprectrum of Cancers," Journal of National Cancer Institute, March 2, 1994, 86(5):356-61. (Exhibit 10) O'Brien, T.S. et al., "Urinary Basic Fibroblast Growth Factor in Patients with Bladder Cancer and Benign Prostatic Hypertrophy," British Journal of Urology, 1995, 76:311-4. (Exhibit 11) Petrakis, Nicholas L., "Nipple Aspirate Fluid in Epidemiologic Studies of Breast Disease," Epidemiologic Reviews, 1993, 15(1):188-95. (Exhibit 12) Rose, David P., "Hormones and Growth Factors in Nipple Aspirates from Normal Women and Benign Breast Disease Patients," Cancer Detection and Prevention, 1992, 16(1):43-51. (Exhibit 13)

ÉX.	A١	ΛI	N	Ε	R

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449*		Docket Number	Ap Sheet 2 of 2
INFORMATION DISCLOSURE STATEMENT		30448.73USU1	Application Number
		Applicant	C709/901;339
m	IN AN APPLICATION	Mai H. Nguyen	1600,00
(Use	Several change is	Filing Date	Group Art UK
2002 6	several sheets if necessary)	July 9, 2001	1743
PADEMARK OFFICE	OTHER DOCUMENTS (Including Author,	Tid. D	0 1
	Sauter, Edward R. et al., "Prostate-Specif Breast Cancer Risk," Cancer Epidemiolog (Exhibit 14)  Sluitz, G. et al., "Serum Evaluation of Bast Cancer Letters, 1995, 94(2):227-31. (Exhibit 14)  Takei, Yoshifumi et al., "Serum Concentrate Clinical Chemistry, 1994, 40(10):1980-1.  Watanabe, H. et al., (Abstract) "Basic Fibrifor Breast Cancer," Molecular Biology of 1992, 3:234a. (Exhibit 17)  Watanabe, Hiroyuki et al., "A Sensitive En Factor," Biochemical and Biophysical Rese (Exhibit 18)  Wrensch, Margaret et al., "Breast Cancer R of Breast Fluid and Prior History of Breast 137(8):829-33. (Exhibit 19)  Wrensch, Margaret R. et al., "Factors Associates Women and Literative Review," Bread 20)	ic Antigen Levels in Nipple A gy, Biomarkers and Prevention (Sic Fibroblast Growth Factor in hibit 15) ations of Basic Fibroblast Growth Factor in Human (Exhibit 16) roblast Growth Factor (February Communications, February (Exhibit 16) roblast Growth Abnorma (Exhibit 16) roblast Growth Factor (February Communications, February (Exhibit 16) roblast Growth Factor (February Communications, February (February Communications) (February Communica	spirate Fluid Correlate with n, December 1996, 5:967-70.  In Cervical Cancer Patients," with Factor in Breast Cancer," an Serum – A Prognostic Test attion) Abstracts, September on Basic Fibroblast Growth ary 28, 1991, 175(1):229-35.  I Cytology in Nipple Aspirates of Epidemiology, April 15, 1993,
MINER	DATE	CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. \*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE